Trenzyme GmbH Licenses SEFEX Cell Line Technology from Celonic AG

Konstanz based contract research organization Trenzyme GmbH and Basel based Celonic AG today announced the closure of a licence agreement on Celonics CHO-K1 based cell line expression platform SEFEX. Under the terms of the deal, Trenzyme acquires the non-exclusive rights and know-how on this technology to establish high performance cell lines for R&D and GMP production purposes for its clients